Amy R Rappaport, Chrisann Kyi, Monica Lane, Meghan G Hart, Melissa L Johnson, Brian S Henick, Chih-Yi Liao, Amit Mahipal, Ardaman Shergill, Alexander I Spira, Jonathan W Goldman, Ciaran D Scallan, Desiree Schenk, Christine D Palmer, Matthew J Davis, Sonia Kounlavouth, Lindsey Kemp, Aaron Yang, Yaojun John Li, Molly Likes, Annie Shen, Gregory R Boucher, Milana Egorova, Robert L Veres, J Aaron Espinosa, Jason R Jaroslavsky, Lauren D Kraemer Tardif, Lindsey Acrebuche, Christopher Puccia, Leiliane Sousa, Rita Zhou, Kyounghwa Bae, J Randolph Hecht, David P Carbone, Benny Johnson, Andrew Allen, Andrew R Ferguson, Karin Jooss
Therapeutic vaccines that elicit cytotoxic T cell responses targeting tumor-specific neoantigens hold promise for providing long-term clinical benefit to patients with cancer. Here we evaluated safety and tolerability of a therapeutic vaccine encoding 20 shared neoantigens derived from selected common oncogenic driver mutations as primary endpoints in an ongoing phase 1/2 study in patients with advanced/metastatic solid tumors. Secondary endpoints included immunogenicity, overall response rate, progression-free survival and overall survival...
March 27, 2024: Nature Medicine